In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic ...

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

What Is Chronic Lymphocytic Leukemia? Chronic lymphocytic leukemia (CLL) is a cancer that affects a type of white blood cell called a "lymphocyte." Lymphocytes help your body fight infection. They're ...

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...